Drug-nutrient interactions in transplant recipients

Journal of Parenteral and Enteral Nutrition

Volumn 25, Issue 3, 2001, Pages 132-141

  Chan, L N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CYCLOSPORIN; FOLIC ACID; HOMOCYSTEINE; VITAMIN;

ARTICLE; ATHEROSCLEROSIS; DIET SUPPLEMENTATION; DRUG ABSORPTION; ELECTROLYTE DISTURBANCE; FOOD DRUG INTERACTION; FRUIT JUICE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; NUTRITIONAL STATUS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VITAMIN D DEFICIENCY;

EID: 0035038313     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607101025003132     Document Type: Article

References (74)

1. Influence of food on the bioavailability of drugs
2. Carnitine deficiency with hyperammonemia associated with valproic acid therapy
3. Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases
4. Amelioration of adverse effects of valproic acid on ketogenesis and liver coenzyme. A metabolism by cotreatment with pantothenate and carnitine in developing mice: Possible clinical significance
5. Valproate-induced hepatoxicity: Protective effect of L-carnitine supplementation
6. The effect of carnitine supplementation in valproate-induced hyperammonaemia
7. Valproate-induced encephalopathy treated with carnitine in an adult
8. Vlaproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure
9. Redefining drug nutrient interactions
10. Immunomodulators: Immunosuppressive agents and immunostimulants
11. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients
12. University of Miami Division of Clinical Pharmacology therapeutic rounds: Drug-induced hyperkalemia
13. Cyclosporin-induced hypomagnesemia and renal magnesium wasting in rats
14. Nephrotoxicity of immunosuppressive drugs
15. Magnesium deficiency and bone loss after cardiac transplantation
16. Association between cyclosporine neurotoxicity and hypomagnesemia
17. Hypomagnesemia with increased metabolism of parathyroid hormone and reduced responsiveness to calcitropic hormones
18. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients
19. Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects
20. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation
21. Evidence for the impairment of the vitamin D activation pathway by cyclosporine A
22. Homocysteine and atherothrombosis
23. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: More evidence from a case-control study
24. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
25. Prospective study of hyperhomocys-teinemia as an adverse cardiovascular risk factor in end-stage renal disease
26. Plasma homocysteine levels and mortality in patients with coronary artery disease
27. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
28. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
29. Homocysteinemia and vascular disease in end stage renal disease
30. Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism
31. Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients
32. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients
33. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine
34. Serum total homocysteine concentration before and after renal transplantation
35. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients
36. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
37. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine
38. Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients
39. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients
40. Improvement of cyclosporine absorption in children after liver transplantation by means of water-soluble vitamin E
41. Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant
42. Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation
43. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers
44. Structure and function of P-glycoprotein in normal liver and small intestine
45. The pharmacological role of P-glycoprotein in the intestinal epithelium
46. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)
47. Grapefruit juice-drug interactions
48. Ethanol enhances the hemodynamic effects of felodipine
49. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
50. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance
51. Grapefruit juice: A possible source of variability in blood concentration of cyclosporin A
52. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients
53. Effect of grapefruit juice on blood cyclosporin concentration
54. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice
55. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function
56. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases
57. Inhibitory effect of grapefruit juice and the active component, naringenin, on CYP1A2 dependent metabolism of caffeine
58. The fate of naringin in humans: A key to grapefruit juice-drug interactions?
59. In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin
60. Quercetin, an in vitro inhibitor of CYP3A4, does not contribute to the interaction between nifedipine and grapefruit juice
61. Grapefruit juice-felodipine interaction: Mechanism, predictability, and effect of naringin
62. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice
63. Grapefruit component interacting with rat and human CYP3A: Possible involvement of non-flavonoid components in drug interactions
64. Identification of 6′7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice
65. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein
66. Grapefruit juice activates P-glycoprotein-mediated drug transport
67. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components
68. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
69. Molecular and physical mechanisms of first-pass extraction
70. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach
71. Grapefruit juice increases felodipine oral bioavailability in humans by decreasing intestinal CYP3A protein expression
72. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
73. Nutrient content and nutrition labeling of several processed Florida citrus juice products
74. Understanding drug-drug interaction